R&D News | pharmaphorum

News

Disappointment as Novo's oral GLP-1 fails in Alzheimer's

GLP-1 agonists have been shown to be beneficial in a lengthening list of diseases, but it seems Alzheimer's disease may not be among them.

News

An older man holds his head in pain while lights flash

Stroke data breathes life back into Bayer's asundexian

Prospects for Bayer's oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.

News

J&J abandons Alzheimer's antibody in setback for tau

Hopes that anti-tau drugs could emerge as treatments for Alzheimer's have been dented by the failure of a phase 2b trial of J&J's posdinemab.

News

Neuralink rival Paradromics cleared to start speech trial

Brain computer interface developer Paradromics has been cleared to start a US clinical trial of its Connexus implant for speech restoration.

News

ADC specialist Solve raises $120m, and other biofinancings

Our round-up of biofinancings is led by a $120m round for ADC specialist Solve, with Aspen, Artios, Profluent, and Gate Bioscience also raising funds.

News

Merck partners Valo on $3bn, AI-based Parkinson's project

Merck has teamed up with Valo Health on a project to apply AI to the discovery of novel drug targets and drugs for Parkinson's.

Disappointment as Novo's oral GLP-1 fails in Alzheimer's

Stroke data breathes life back into Bayer's asundexian

J&J abandons Alzheimer's antibody in setback for tau

Neuralink rival Paradromics cleared to start speech trial

ADC specialist Solve raises $120m, and other biofinancings

Merck partners Valo on $3bn, AI-based Parkinson's project

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks